Publications by authors named "Stacy Boylan"
Invest New Drugs
January 2005
Article Synopsis
- A phase I clinical trial evaluated the safety and pharmacokinetics of CEP-701, an oral tyrosine kinase receptor inhibitor, in 30 patients with advanced carcinomas.
- The maximum tolerated dose (MTD) was not reached at higher doses, with dose-limiting toxicities (DLTs) observed notably at 80 and 120 mg BID, leading to gastrointestinal issues that limited tolerance above 40 mg BID.
- Although there were no significant tumor responses, some patients experienced stable disease for extended periods, prompting the recommendation of 40 mg BID for further phase II trials.
